Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Alexander Kutz MD, MPH, MSc

Alexander Kutz MD, MPH, MSc

Medical University Department, Division of General Internal and Emergency Medicine, Kantonsspital Aarau, Aarau, Switzerland; Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts

Dr. Kutz is an internist and endocrinologist. His scientific work focuses on health services research using real-world data. Apart from development of integrative health care models to improve patient transition in the hospital setting, using a Swiss health care claims database, he also focuses on outcome research in mainly older, frail, and multimorbid adults. His major scientific interest involve the clinical epidemiology of mainly vulnerable patients with metabolic and endocrine disorders.

Dr. Kutz completed his medical training at the University of Basel in Switzerland. He received his Board Certification for Internal Medicine and Endocrinology and Diabetology in Switzerland and earned a Master degree in Science at Dresden International University and at Harvard School of Public Health in Boston. In 2021, he earned a Master of Public Health in clinical effectiveness at Harvard School of Public Health in Boston.

Dr. Kutz joined in 2021 the Division of Pharmacoepidemiology and Pharmacoeconomics at the Brigham and Women’s Hospital and the Harvard Medical School in Boston for a postdoctoral fellowship supported by an advanced postdoc mobility fellowship from the Swiss National Science Foundation. One of his main focus of interest is the effectiveness and safety of newer antidiabetic medication in people that are usually excluded from clinical trials.


Dr. Kutz is supported by a Postdoc.Mobility grant (P400PM_194479 / 1) from the Swiss National Science Foundation and by an educational grant from Novo Nordisk.